NCT05448677View on ClinicalTrials.gov

Ezurpimtrostat Autophagy Inhibitor in Association With Atezolizumab-Bevacizumab in First Line Treatment of Unresectable Hepatocellular Carcinoma

PHASE2TerminatedINTERVENTIONAL
Enrollment

3

Participants

Timeline

Start Date

December 15, 2022

Primary Completion Date

March 8, 2024

Study Completion Date

March 8, 2024

Conditions
Hepatocellular Carcinoma
Interventions
DRUG

Ezurpimtrostat

Patients in the experimental arm will be instructed to take their assigned oral dose every day.

DRUG

Atezolizumab

Atezolizumab will be administered by IV infusion at a fixed dose of 1200 mg on Day 1 of each 21-days cycle

DRUG

Bevacizumab

Bevacizumab will be administered by IV infusion at a dose of 15 mg/kg on Day 1 of each 21-day cycle.

Trial Locations (1)

38043

University Hospital, Grenoble

Sponsors

Collaborators (1)

Genoscience Pharma
All Listed Sponsors
collaborator

Genoscience Pharma

INDUSTRY

lead

University Hospital, Grenoble

OTHER

NCT05448677 - Ezurpimtrostat Autophagy Inhibitor in Association With Atezolizumab-Bevacizumab in First Line Treatment of Unresectable Hepatocellular Carcinoma | Biotech Hunter | Biotech Hunter